Subcutaneous Remsima (infliximab) launched in UK
This is the first subcutaneous formulation of infliximab and is licensed for treatment of rheumatoid arthritis. Celltrion has also submitted a further variation to the marketing authorisation of the subcutaneous drug to include the inflammatory bowel disease indication.
Source:
PharmaTimes